These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8137058)

  • 1. Need for treatment of elevated plasma fibrinogen levels in cerebrovascular disease.
    Clark WM; Coull BM; Beamer NB
    Heart Dis Stroke; 1993; 2(6):503-6. PubMed ID: 8137058
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions: the Ohasama study.
    Aono Y; Ohkubo T; Kikuya M; Hara A; Kondo T; Obara T; Metoki H; Inoue R; Asayama K; Shintani Y; Hashimoto J; Totsune K; Hoshi H; Satoh H; Izumi S; Imai Y
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):963-8. PubMed ID: 17272746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrinogen: a risk factor].
    Potron G; N'Guyen P; Pignon B
    J Mal Vasc; 1996; 21(3):126-32. PubMed ID: 8965039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and strokes--reducing the risk.
    Jackson G
    Int J Clin Pract; 1999; 53(3):159. PubMed ID: 10665124
    [No Abstract]   [Full Text] [Related]  

  • 5. Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke.
    Elger B; Laux V; Schwarz M
    Arzneimittelforschung; 1997 Aug; 47(8):895-9. PubMed ID: 9296273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancrod: clinical indications and methods of use.
    Wright JG; Geroulakos G
    Semin Vasc Surg; 1996 Dec; 9(4):315-28. PubMed ID: 8958608
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reduced levels of lipids and cerebrovascular disease--benefits and risks?].
    Olsson JE
    Lakartidningen; 2002 Apr; 99(17):1967-9. PubMed ID: 12043425
    [No Abstract]   [Full Text] [Related]  

  • 8. Taking the bite out of snake venoms.
    Senior K
    Lancet; 1999 Jun; 353(9168):1946. PubMed ID: 10371585
    [No Abstract]   [Full Text] [Related]  

  • 9. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C
    Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM.
    Coppola G; Corrado E; Muratori I; Tantillo R; Vitale G; Lo Coco L; Novo S
    Int J Cardiol; 2006 Jan; 106(1):16-20. PubMed ID: 16321660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling acute elevation of plasma fibrinogen with ancrod.
    Cole CW
    Cerebrovasc Dis; 1998 Jan; 8 Suppl 1():29-34. PubMed ID: 9547026
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
    Laupacis A
    Can J Cardiol; 1998 May; 14(5):659, 662; author reply 663, 665. PubMed ID: 9627518
    [No Abstract]   [Full Text] [Related]  

  • 13. Trials and tribulations.
    Packard CJ
    Int J Clin Pract Suppl; 2002 Oct; (132):3-10. PubMed ID: 12425357
    [No Abstract]   [Full Text] [Related]  

  • 14. Ancrod in the treatment of acute ischemic stroke. A review of clinical data.
    Atkinson RP
    Cerebrovasc Dis; 1998 Jan; 8 Suppl 1():23-8. PubMed ID: 9547025
    [No Abstract]   [Full Text] [Related]  

  • 15. Stroke prevention: a medical obligation.
    Barnett HJ; Meldrum HE
    J Fla Med Assoc; 1997; 84(4):239-49. PubMed ID: 9342911
    [No Abstract]   [Full Text] [Related]  

  • 16. C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease.
    Zacho J; Tybjaerg-Hansen A; Nordestgaard BG
    Scand J Clin Lab Invest; 2009; 69(4):442-6. PubMed ID: 19533498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian, Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
    Mant MJ
    Can J Cardiol; 1998 May; 14(5):663; author reply 663, 665. PubMed ID: 9627519
    [No Abstract]   [Full Text] [Related]  

  • 18. A rebuttal--the Rsal polymorphism in the alpha-fibrinogen gene and response of plasma fibrinogen to physical training.
    Davey G; Cook D; McKeigue P
    Thromb Haemost; 2001 Jan; 85(1):188. PubMed ID: 11204579
    [No Abstract]   [Full Text] [Related]  

  • 19. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of cardiovascular risk factors on hemorheologic parameters in cerebrovascular patients].
    Szapáry L; Szóts M; Horváth B; Márton Z; Alexy T; Késmárky G; Juricskay I; Nagy F; Gaál V; Pálfi A; Koltai K; Tóth K
    Orv Hetil; 2003 Jun; 144(22):1085-90. PubMed ID: 12847818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.